Ipsen, Marengo ink $1.2B biobuck deal to treat cold tumors
Using Marengo’s TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaborationResearch will focus on...
CAMBRIDGE, Mass., Nov. 10, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor V? chain (TCR V?) to selectively activate the right T cell subsets to fight cancer, today will be presenting preclinical data that characterizes the mechanism of action and confirms robust anti-tumor activity for its novel T cell-activating antibody STAR0602 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston. The data disclosed also includes extensive characterization pharmacokinetic (PK) and pharmacodynamic (PD) relationships of STAR0602 in NHP studies. These data support the modelling of human pharmacology and inform the design of START-001, a Phase 1/2 clinical trial of STAR0602 monotherapy in a biomarker enriched, tissue agnostic, PD-1 refractory cancer patient population.
CAMBRIDGE, Mass., Oct. 28, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor V? chain (TCR V?) to selectively activate the right T cell subsets to fight cancer, today presented the first preclinical proof-of-concept data on STAR0602, its novel TCR agonist antibody, during the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (ENA) in Barcelona, Spain. The data presented showed potent anti-tumor activity of STAR0602 in a range of solid tumor models, including those refractory to check point inhibitors like PD-1/PD-L1.
Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo Therapeutics, Inc. today announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization.
Marengo Therapeutics has received further validation for its STAR platform for T-cell activators, with Ipsen paying $45 million upfront to take two cancer candidates into the clinic.
CAMBRIDGE, Mass., March 9, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that selectively activate T cells via the T cell receptor V? chain to combat cancer, today announced that it will participate in the following investor, scientific, and industry conferences.
CAMBRIDGE, Mass., Jan. 6, 2022 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel therapeutics that directly target the V? chain of the T cell receptor (TCR) to activate the right T cell subsets to fight cancer, today announced that Zhen Su, M.D., MBA, Chief Executive Officer of Marengo Therapeutics, will present at the 40th Annual J.P. Morgan Health Care Conference on Tuesday, January 11, 2022, at 2:30 p.m. ET/11:30 am PT.